Biotech Starts 12-Week Obesity Drug Trial
A small biotech company has begun a 12-week trial of an oral drug candidate that works through a pathway different from GLP-1 and amylin hormones.
Updated on Nov. 20, 2026 in Diabetes

A biotech company has received regulatory approval for a 12-week clinical trial of XEN-D0501 in people with obesity. The trial assesses safety, tolerability, pharmacokinetics and efficacy at doses higher than previously studied.
Why it matters
Most current obesity treatments act on GLP-1 or amylin hormones, so an oral candidate targeting a different receptor could broaden the range of options being tested. The trial's early results will show whether this approach is tolerable at higher doses.
The trial will enroll up to 46 participants for 12 weeks, with doses rising from 4 mg to a maximum of 16 mg twice daily if tolerated. Results on efficacy and safety have not been released, and the trial remains ongoing.
The details
XEN-D0501 is an oral drug candidate that acts as a TRPV1 antagonist, a receptor involved in pain and inflammation rather than metabolic hormone signaling. Participants start at 4 mg twice daily and move up to 16 mg twice daily only if they tolerate the dose.
Timeline
Article on the GLP-1 obesity treatment race published November 20, 2026.
Big Picture
Current obesity drug development is dominated by GLP-1 receptor agonists, and this TRPV1 antagonist trial tests a mechanism outside that class. Its outcome will show whether non-hormonal pathways can contribute to the next generation of oral weight-loss treatments.
The trial is still in an early stage, so the drug is not available to patients outside the study. Anyone with obesity should continue to rely on approved treatments and discuss options with a clinician.
The takeaway
Early-stage trials of drugs outside the GLP-1 class are still testing safety and dosing, so no conclusions about effectiveness can yet be drawn. Readers should treat this as a step in research rather than a new treatment option.
Further reading
For more on the drugs competing in this space, see our coverage of Diabetes.
Source note: This article includes information reported by Manufacturingchemist.



